

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CHANGE OF DIRECTORS AND COMPOSITION OF THE BOARD COMMITTEES;
AND
PROPOSED ADOPTION OF THE NEW MEMORANDUM
AND ARTICLES OF ASSOCIATION**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”) pursuant to Rule 13.51(1) and Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

CHANGE OF DIRECTORS AND COMPOSITION OF THE BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces the following changes to the Board and the Board’s committees with effect from 30 September 2025:

Resignation of non-executive Directors

- (1) Mr. Hiroshi Shirafuji (“**Mr. Shirafuji**”) has resigned as a non-executive Director, the honorary chairman and a member of the strategic committee of the Company (the “**Strategic Committee**”) in order to devote more time to his other business endeavours. Mr. Shirafuji has confirmed to the Company that he has no disagreement with the Board. The Company confirms that there is no matter relating to the resignation of Mr. Shirafuji that needs to be brought to the attention of the shareholders of the Company.
- (2) Mr. Norihiro Ashida (“**Mr. Ashida**”) has resigned as a non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”) in order to devote more time to his other business endeavours. Mr. Ashida has confirmed to the Company that he has no disagreement with the Board. The Company confirms that there is no matter relating to the resignation of Mr. Ashida that needs to be brought to the attention of the shareholders of the Company.

As at the date of this announcement, Mr. Shirafuji and Mr. Ashida have been appointed as advisors of the Company. The Company would like to express its sincere gratitude to both gentlemen for their dedicated efforts and valuable contributions to the Group during their terms as directors, and looks forward to their continued professional guidance, suggestion and advice for the development of the Group in the future.

Appointment of non-executive Directors

- (1) Dr. Feng Gu (谷峰) (“**Dr. Gu**”) has been appointed as a non-executive Director and a member of each of the nomination committee (the “**Nomination Committee**”) and the remuneration committee (the “**Remuneration Committee**”) of the Company.

Dr. Gu, born in 1972, was appointed as a non-executive Director on 30 September 2025. Dr. Gu has over 20 years of experience in financial management, enterprise management, industrial capital operations, equity investment, and corporate governance. Dr. Gu currently serves as the chief finance and investment officer of Shanghai Industrial Investment (Holdings) Company Limited, deputy CEO of Shanghai Industrial Holdings Limited (a company listed on the Stock Exchange (stock code: 0363)), and executive director and president of SIIC Shanghai Capital Management Co., Ltd.. Dr. Gu has been in charge of finance, investment and financial business in several conglomerates and has extensive experience in mergers and acquisitions, equity investment, reorganization and integration, as well as listing and financing. From 1997 to 2001, Dr. Gu served as head of the financial and accounting department at SAIC General Motors Corporation Limited. From 2001 to 2005, he held positions of deputy manager of the finance department and deputy manager of the asset operation department at Shanghai Automotive Industry Corporation (Group). From 2005 to 2016, he successively served as executive director of capital operations, executive director of finance, and chief financial officer at SAIC Motor Corporation Limited, and concurrently served as the person-in-charge of several subsidiaries. From 2017 to 2020, he co-founded Aiways Automobiles and served as its chief executive officer. From 2020 to 2023, he served as the chief financial and investment officer of Bailian Group Co., Ltd. Dr. Gu holds the title of senior accountant in PRC and is a non-practicing member of China Certified Public Accountants (CPA), a member of The Association of Chartered Certified Accountants (“**ACCA**”) and a member of ACCA China Expert Forum.

Dr. Gu currently also serves as an independent director of Shanghai Highly (Group) Co., Ltd.(a company listed on the Shanghai Stock Exchange (stock code: 600619)) and from May 2020 to April 2024, he has served as an independent director of Gemdale Corporation (a company listed on the Shanghai Stock Exchange (stock code: 600383)).

He obtained his Ph.D in Business Administration from Tongji University in August 2011.

Dr. Gu is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (the “**SFO**”).

Save as disclosed above, Dr. Gu has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Dr. Gu will enter into a letter of appointment with the Company, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Gu will not receive any emolument for serving as a non-executive Director.

There is no information which is discloseable nor is Dr. Gu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Gu that need to be brought to the attention of the shareholders of the Company.

- (2) Dr. Qingbing Men (門慶兵) (“**Dr. Men**”) has been appointed as a non-executive Director, a member of the Audit Committee and the chairman of the Strategic Committee.

Dr. Men, born in 1977, was appointed as a non-executive Director on 30 September 2025. Dr. Men has over 20 years of experience in finance and investment. He currently serves as the general manager and deputy party secretary of Shanghai Pudong Innovation Investment and Development (Group) Co., Ltd., and a council member of the Shanghai Institute of Science and Technology Innovation and Finance. From September 2004 to April 2006, Dr. Men worked at Greenland Group based in Shanghai. From April to July 2006, Dr. Men worked at SIIC. From July 2006 to January 2010, he served at the Development and Reform Committee of Pudong New District. From January 2010 to January 2023, Dr. Men worked at the Finance Bureau of Pudong New District, successively holding positions including senior staff member, deputy director, director and deputy director general of the institutional development service division. From January 2023 to March 2024, Dr. Men joined Shanghai Pudong Investment Holdings (Group) Co., Ltd. (now renamed as Shanghai Pudong Innovation Investment and Development (Group) Co., Ltd.), where he served as the deputy general manager and party committee member.

Dr. Men obtained his Ph.D. in Technical Economics and Management from Tongji University in September 2004.

Dr. Men is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Dr. Men has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Dr. Men will enter into a letter of appointment with the Company, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Men will not receive any emolument for serving as a non-executive Director.

There is no information which is discloseable nor is Dr. Men involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Men that need to be brought to the attention of the shareholders of the Company.

The Board hereby expresses its warmest welcome to Dr. Gu and Dr. Men for their new appointments.

- (3) Dr. Zhaohua Chang ceases to be a member of the Remuneration Committee and the chairman of the Strategic Committee.
- (4) Mr. Jonathan H. Chou has been appointed as a member of the Nomination Committee.

PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

To strengthen the Board' governance over the Company's major decisions, and after taking into consideration the actual situation of the Company, the Board proposes to make amendments (the "**Proposed Amendments**") to the fourth amended and restated memorandum and articles of association of the Company (the "**Existing Articles of Association**"). The changes to be brought about by the Proposed Amendments relate to board resolution requirement over certain major decisions of the Company. These major decisions of the Company primarily include (i) the granting of options or other subscription rights over shares by the Company; (ii) the appointment of, removal of and making adjustments to the remuneration of the C-suite of the Company; (iii) the amendment and restatement of the Company's Memorandum and Articles of Association; (iv) the connected transactions and the continuing connected transactions other than those that are fully exempted under the Listing Rules; (v) the spin-off or sale of operating subsidiaries of the Company, or any other transaction that may substantially result in the deconsolidation of the financial statements of the operating subsidiaries or the sale of an operating subsidiary's major assets; (vi) any plan or proposal of the Company to issue shares, convertible bonds or any securities or bonds that can be convertible into or exercisable for shares in the Company; (vii) certain types of proposed debt financing of or guarantee by the Company other than re-financing or renewal thereof; (viii) the adoption, amendment, and adjustment of exercise price of the Company's and its subsidiaries' share incentive plans or share award plans and other similar plans; (ix) the granting of options or awards under the Company's and its subsidiaries' share incentive plans or share award plans and other similar plans to the C-suite of the Company; and (x) any non-revenue generating transactions of the Company and its subsidiaries. In view of the Proposed Amendments, the Board proposes to adopt a new fifth amended and restated memorandum and articles of association of the Company (the "**New Articles of Association**") in substitution for, and to the exclusion of, the Existing Articles of Association.

The Proposed Amendments and adoption of the New Articles of Association are subject to approval by the Shareholders by way of a special resolution at the forthcoming extraordinary general meeting of the Company (the "**EGM**").

A circular reflecting, among other matters to be tabled at the EGM, further details of the Proposed Amendments and the notice of the EGM will be despatched to the Shareholders in due course.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 30 September 2025

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purposes only*